ONCOBIT - Key Persons
Job Titles:
- Life Scientist With a
- Quality and Regulatory Affairs Manager
Ayana Martins is a life scientist with a PhD in computational biology from the University of São Paulo. In 2020, she co-founded a start-up in the diagnostic industry and delved into the world of regulatory and quality affairs. At Oncobit, Ayana is responsible for enabling market access and ensuring that all products meet the highest standards of quality and safety.
Job Titles:
- Head of Software Development
Barbara Geissmann holds a PhD in Theoretical Computer Science from ETH Zurich and an MSc in Computer Science from ETH Zurich. She has been working closely with Oncobit since 2019 and joined the company in 2021 as a Senior Computer Scientist. With her expertise in algorithms and optimization, Barbara Geissmann contributes to linking medicine and computer science.
Bjoern Biedermann holds a PhD in cell biology from the University of Basel. He has been working in the life science and diagnostic industry for more than 12 years, leading various teams in international corporations as well as in start-up companies. His area of expertise lies in sales, marketing, business development and customer support. At Oncobit, Bjoern is responsible for building scalable commercial structures to grow Oncobit's international business.
Job Titles:
- Member of the Board of Directors
Christian Schilling, MD, PhD is Managing Partner at AVANTECA Partners AG, a privately held asset management company based in Basel, Switzerland. He is a former senior executive of Boehringer Ingelheim and has over 25 years of experience in Big Pharma, including strategic and operational roles in research, clinical development, marketing and sales as well as country management. He also held executive roles in business development and M&A.
Claudia Scheckel has a PhD in biochemistry from the University of Basel and a degree in management from the HSG. She has worked for almost 10 years in different disciplines of biomedical research at The Rockefeller University in New York and the University Hospital of Zurich and is driven by the impact science can have for our society. Claudia Scheckel joined Oncobit as co-founder and CEO to translate the latest scientific findings into benefits for patients.
Job Titles:
- Member of the Board of Directors
Daniel Schoener, PhD is a Diagnostics technology leader and has been working as an independent innovation consultant and angel investor since early 2020. During his corporate career with multinationals such as Roche Diagnostics and PerkinElmer, Daniel Schoener has directed late-stage tech integrations, global tech transfers, R&D partnerships and held corporate leadership positions in Business and R&D. Daniel Schoener is passionate about radical innovation and advises startups internationally.
Job Titles:
- Head of Product Development
Elena Clementi has a PhD in Cancer Biology from the University of Zürich and a Master's degree in Cellular and Molecular Biotechnology from the University of Trento. Through her academic experience she has acquired a profound knowledge in molecular biology, with a special focus on cancer research. Elena Clementi joined Oncobit in April 2021 as a product developer to contribute to the design and development of innovative tests that can positively impact patients' lives.
Evelina Blomberg has a master's degree in Biomedicine from the Karolinska Institute and a PhD in Cancer Biology from the University of Zurich. Evelina has more than 6 years of experience in cancer research and has worked in various labs. Evelina joined Oncobit in December 2022 as a research associate to develop and validate Oncobit's diagnostic and monitoring solutions to enable personalized cancer care.
Francisco Garcia Asencio has a bachelor's degree in biotechnology and a master's degree in neuroscience. During his PhD, he developed a broad set of skills in molecular and cellular biology and characterized molecular pathways important for cancer progression. He has more than six years of work experience in molecular biology, including the diagnostic industry. Francisco started as a Research Associate in January 2023 to develop and validate Oncobit's diagnostic and monitoring solutions to enable personalized cancer care.
Job Titles:
- Associate Professor of Translational Dermato - Oncology at the University of Zurich
Dr. Mitch Levesque is associate professor of translational dermato-oncology at the University of Zurich and Scientific Department Leader in the Department of Dermatology at the University Hospital Zurich. He has over 20 years of experience in experimental biology, and he is head of the University Research Priority Program (URPP) translational cancer biobank. He is on the steering board of the Functional Genomics Center Zurich and has numerous collaborations with industrial partners including Roche, Novartis, and BMS. Prof. Levesque is a recognized international leader in melanoma translational oncology and has been on the organizing committee of the world society for melanoma research.
Job Titles:
- President of the Board of Directors
Ruedi Gygax, PhD, looks back at 25 years of supporting startups, including 12 years as a managing director at the Novartis Venture Fund, 6 years as a part time partner at a financial venture fund and more than 10 years as a business angel, coach and expert at CTI/Innosuisse. He has served on many boards of Swiss and foreign companies. His education comprises studies of physical chemistry at the University of Basel and Stanford University. He started his career at Ciba-Geigy in the fields of process safety and materials research.
Job Titles:
- Head of Clinical Operations
Sandra Freiberger-Rupp holds a PhD in Cancer Biology from the University of Zurich and has more than 10 years of experience in the field of cancer research, including melanoma. For the last 6 years she has been responsible for routine molecular diagnostics of head & neck cancer and skin cancer at the Department of Pathology and Molecular Pathology, University Hospital Zurich. Sandra joined Oncobit in January 2023 as Performance Evaluation Manager of Oncobit's diagnostic and monitoring solutions.
Job Titles:
- Co - Founder
- Member of the Board of Directors
Stephany Orjuela has a PhD in biostatistics from the University of Zurich, and a BSc in biology from the National University of Colombia. She has almost 6 years of experience in the bioinformatic field, and has contributed to the development of several software solutions used by the scientific community. As part of the Oncobit software team, she continues to work at the intersection of medicine and bioinformatics.
Job Titles:
- Co - Founder
- Member of the Board of Directors
Job Titles:
- Professor at the University Hospital Zurich
Michael Krauthammer is a professor at the University Hospital Zurich and the University of Zurich. His career spans both medicine and biomedical informatics. He received his M.D. at the University of Zurich, Switzerland. After clinical work in internal medicine and surgery, he obtained a Ph.D. in biomedical informatics at Columbia University in New York. Michael Krauthammer maintained a computational lab at Yale University School of Medicine between 2004 and 2018, before moving back to Zurich in 2018.